IBD Clinical Trial - Role of 90K/Mac-2 BP as an Indicator of Early

Status Not yet recruiting

Clinical Trial Summary

The aim of this study is to analyze the relationship between 90K serum levels measured at baseline and after induction in IBD patient undergoing infliximab therapy, in order to clarify the role of serum 90K as an adjuvant biomarker for IBD patients in the active phase. Furthermore, the study aims to evaluate the clinical usefulness of this new biomarker in the management of IBD patients undergoing infliximab therapy.

Clinical Trial Description

Type of the Study: The current work will be single cohort study. Study settings: IBD outpatient clinic at Rajhy gastroenterology and Hepatology Hospital at Assiut University Hospital. Study Duration: June 2023- June 2024 Study population: Participants will be 50 patients were recently diagnosed with Inflammatory Bowel Disease (IBD), Crohn's disease (CD) and Ulcerative Colitis (UC), undergoing the anti-TNF drug infliximab. Infliximab therapy will be administered intravenously initially at a dose of 5 mg/kg/ dose, and then after two and six weeks after the first dose, and fulfill the following inclusion criteria Inclusion Criteria: 1. Adult male and female patients aged 18-60 years old. 2. IBD patients, diagnosis was confirmed by biopsy and histopathology, scheduled for treatment with anti-TNF therapy, Infliximab, and no previous treatment with anti-TNF therapy. Exclusion Criteria: 1. Comorbidities (assessed with the Charlson Comorbidity Index). 2. Ongoing immunosuppressive or immunomodulatory therapy. 3. A malignant neoplasm in the last 10 years. 4. Pregnancy or breast feeding. 5. The need for artificial nutrition. Study assay: 1. History taking and clinical examination, including the time and duration of diagnosis, manifestations of disease severity, and previous treatment received. 2. Laboratory investigations: A. Routine investigations: such as complete blood count, liver function test (including serum albumin, liver enzymes, bilirubin), kidney function test (serum urea and creatinine, GFR), ESR and C - reactive protein. B. The concentration of serum 90K glycoprotein is determined by ELISA assay, according to the manufacturer's instruction. Serum levels will be withdrawn before the first dose and after the third dose. Statistical Tests: Statistical tests will be performed with frequency and cross tabulations for categorical variables. Data will be reported as Mean+/- Standard Deviation (M +/- SD) for all numerical variables. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05960162
Study type	Observational
Source	Assiut University
Contact
Status	Not yet recruiting
Phase
Start date	July 17, 2023
Completion date	July 17, 2024

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04269720` - Biofeedback in Pediatric Inflammatory Bowel Disease	N/A
Recruiting	`NCT04457934` - Effectiveness of PLENVU in the General Screening Population and Patients With IBD
Completed	`NCT01369355` - A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)	Phase 3
Recruiting	`NCT06146816` - The Assessment of Infrared Treatment for Crohn's Disease	N/A
Recruiting	`NCT05624801` - Cholecalciferol in Chronic Inflammatory Bowel Diseases	Phase 3
Recruiting	`NCT05086562` - Prevalence of Chronic Abdominal Pain in Migraneurs
Recruiting	`NCT03935451` - Postoperative Extended Venous Thromboprophylaxis in Inflammatory Bowel Disease	Early Phase 1
Recruiting	`NCT05578768` - Prediction of IBD Disease Activity in Individual Patients Based on PROMs and Clinical Data
Completed	`NCT01653054` - Anal Dysplasia in Patients With Inflammatory Bowel Disease	N/A
Completed	`NCT04131504` - Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)
Recruiting	`NCT03952364` - The PRECIOUS Study: Predicting Crohn's & ColitIs Outcomes in the United States
Enrolling by invitation	`NCT05414955` - Boom-IBD Clinical Trial	N/A
Enrolling by invitation	`NCT04094324` - Mental Health in Children and Youth Within Pediatric Care
Suspended	`NCT04225819` - Adjunctive Treatment With Vitamin D3 in Patients With Active IBD	N/A
Recruiting	`NCT03366090` - Immunological Profiles in Inflammatory Bowel Disease	N/A
Completed	`NCT03750565` - Multiple Dose Ethnobridging PK Study in Healthy Subjects	Phase 1
Recruiting	`NCT02970149` - Identifying a Sleep Screener for Disease Relapse in Children With Inflammatory Bowel Disease	N/A
Completed	`NCT02622139` - Multispectral Optoacoustic Tomography (MSOT) for the Evaluation of Disease Activity in Inflammatory Bowel Diseases (IBD)	N/A
Completed	`NCT02364973` - Combined PET-MRI in the Diagnostics of Chronic Inflammatory Bowel Diseases (IBD)- a Feasibility Study
Not yet recruiting	`NCT06090045` - Airway Involvement In Inflammatory Bowel Disease

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Role of 90K/Mac-2 BP as an Indicator of Early Response to Infliximab Therapy in IBD Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms